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The publication of the U.K. Prospec-tive Diabetes Study (UKPDS) in1998 helped to shape the manage-
ment of type 2 diabetes in recent years (1).
The study demonstrated several points.
First, sulfonylureas are as safe as insulin in
controlling blood glucose. Second, met-
formin reduced cardiovascular disease in
an overweight subgroup. Third, the
same benefit of glycemic control in re-
ducing microvascular disease (previ-
ously noted in type 1 diabetes) is
applied equally to patients with type 2
diabetes. A separation in A1C of1% in
the UKPDS reduced the risk of micro-
vascular disease (largely diabetic reti-
nopathy) by 25%. This reflected the
data from the Diabetes Control and
Complications Trial, where a separation
in A1C of 2% in intensive and standard
groups led to a reduction in microvas-
cular disease of 50% (2).
A fourth demonstration was that
there was no significant reduction in ma-
crovascular disease but a trend toward
fewer myocardial infarctions with more
intensive glucose control. Fifth, using the
current treatment of the time (first-
generation sulfonylureas, human ultra-
tard insulin, or metformin), it proved
impossible to maintain glucose control,
which tended to deteriorate throughout
the study. It is now generally believed
that the progressive fall in endogenous
insulin production as -cell numbers
decline makes it difficult, if not impos-
sible, to maintain tight control using
standard treatment. Sixth, the UKPDS
also showed that in those patients with
hypertension, lowering blood pressure
(BP) to moderate levels with either cap-
topril or atenolol could reduce micro-
vascular disease (3).
In a subsequent study, the UKPDS in-
vestigators presented the rates of bothmi-
cro- and macrovascular disease according
to the achieved levels of A1C during the
study (4). They showed a linear relation-
ship between A1C and both groups of
complications. The implication of the ar-
ticle was that if glycemic control could be
tightened below the levels achieved in the
UKPDS, then it might be possible to re-
duce rates, not only of microvascular
complications, but also cardiovascular
disease as well.
The aim of the glucose arm of the Ac-
tion in Diabetes and Vascular Disease:
Preterax and Diamicron MR Controlled
Evaluation (ADVANCE) trial (5) was to
build on the information gained by the
UKPDS and to answer the question as to
whether intensifying glucose control to
achieve an A1C of6.5% would provide
additional benefit in reducing the risk of
both micro- and macrovascular disease.
ADVANCE also asked questions
about BP lowering in patients with type
2 diabetes. The aims of the BP arm were
to establish whether routine provision
of BP-lowering therapy produced addi-
tional benefits in terms of macro- and
microvascular disease, irrespective of
baseline BP, and added to the benefits
produced by other cardiovascular pre-
ventive therapies, including ACE
inhibitors.
TRIAL DESIGN— The trial involved
215 collaborating centers in 20 countries
from Asia, Australia, Europe, and North
America. It was designed to randomize
over 10,000 patients with established
type 2 diabetes in a factorial design (Table
1), resulting in treatment in four catego-
ries: 1) intensive glucose lowering (in-
cluding gliclazide MR) and additional
“routine” BP lowering (perindopril/
indapamide combination), 2) standard
glucose therapy and routine BP lowering,
3) intensive glucose lowering and pla-
cebo; and 4) standard glucose therapy
and placebo (6).
Patients were included if they had
type 2 diabetes and were aged55 years
with an additional risk factor for a vascu-
lar event, any level of BP, and any level of
glucose control with no immediate indi-
cation for insulin treatment. After a
6-week prerandomization run-in, during
which they received a fixed combination
of perindopril (2 mg) and indapamide
(0.625 mg) and standard guidelines-
based blood glucose control, patients
were randomized in a factorial design to
either a perindopril/indapamide combi-
nation or placebo and either an intensive
glucose-lowering strategy aiming for an
A1C target of6.5% or standard glucose-
lowering strategy.
Subjects in the intensive glucose con-
trol arm received gliclazide MR and any
other additional therapy to achieve these
glucose targets. Subjects in the standard
arm received therapy according to local
guidelines; although if they required a
sulfonylurea, then any medication other
than gliclazide could be used.
Patients in the intensive glucose arm
made clinic visits more frequently, at-
tending three monthly after the first 6
months compared with 6 monthly visits
in patients allocated to standard therapy.
Other measures that were used to
tighten control in the intensive arm in-
cluded encouraging investigators to pro-
mote lifestylemanagement such as weight
loss and exercise; maximizing the dose of
gliclazide MR, adding other oral agents;
and adding long-acting insulin, used as
basal bedtime insulin, with rapid-acting
insulin added as required, starting with
the main meal of the day.
Those allocated to standard therapy
received treatment according to local
practice. Outcomes were recorded at 6
monthly intervals with the exception of
retinopathy, albumin-to-creatinine ratio,
mini mental scores, and quality of life,
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which were recorded at 2 years, 4 years,
and at the end of the study.
The primary outcome was a compos-
ite of macrovascular (myocardial infarc-
tion, stroke, or cardiovascular death) and
microvascular (retinopathy or nephropa-
thy) events. Secondary outcomes in-
cluded heart failure, hospitalization, all-
cause mortality, and dementia.
The sample size was calculated based
on epidemiological studies reporting the
association of A1C with vascular events
and assumed a 1% reduction in A1C be-
tween groups and 6 mmHg reduction in
systolic BP, a 16% reduction in microvas-
cular ormacrovascular events based on an
annual event rate of 3% for each. The
analysis was based on the intention-to-
treat principle. After 3 years of the trial,
overall event rates were occurring at
around 2% and separation of A1C was
1%. Without access to unblinded data,
it was therefore decided to combine the
analysis of the primary end point (i.e.,
macrovascular and microvascular dis-
ease) and extend the duration of the glu-
cose-control arm by 18 months.
RESULTS
Patient characteristics
The progress of subjects through the trial
is shown in Fig. 1. A total of 11,140 pa-
tients were randomized into the two glu-
cose arms with a median follow-up of 5
years. Baseline characteristics are shown
in Table 1. The mean age was 66 years,
Table 1—Factorial design: description of the possible assigned therapies
Intensive glucose control Standard glucose control
Routine BP-lowering therapy Routine BP-lowering therapy
Intensive glucose control Standard glucose control
Placebo Placebo
Figure 1—Enrollment, randomization, and follow-up of study participants.
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known duration of diabetes 8 years, and
BMI 28 kg/m2. Mean A1C at entry was
7.5%. About one-third of the patients had
a history of previous macrovascular dis-
ease, 71% were taking sulfonylureas at
entry, and 60% were on metformin.
The BP arm of the study ran for an
average of 4.3 years: the results, pub-
lished in The Lancet in 2007 (7), showed
that a combination of indapamide and
perindopril reduced mortality, coronary
events, and diabetic nephropathy regard-
less of the initial BP.
A1C and glucose-lowering therapy
By the end of follow-up, A1C in the inten-
sive group had fallen to a mean of 6.5%
compared with 7.3% in the standard
group (Fig. 2). A1C fell progressively in
the intensive group, reaching 6.5% after
2–3 years’ duration of the trial. By the end
of the trial, over 90% of patients were still
taking a sulfonylurea (gliclazide MR) in
the intensive group compared with 69%
in those allocated to standard therapy. A
total of 74% were taking metformin (vs.
67% in the standard group), 40%were on
insulin (vs. 24%), and 17% were taking a
glitazone compared with 11% in the stan-
dard group.
Effect of glycemic control on other
risk factors
Systolic BP was significantly lower in in-
dividuals allocated to intensive glucose
control by the end of follow-up (135.5 vs.
137.9 mmHg, average difference during
follow-up 1.6 mmHg; P  0.001). The
difference was present at the 3-month
visit and all subsequent visits. There were
no differences in diastolic BP or lipids.
The weight of those assigned to intensive
control remained generally stable,
whereas those in the standard group had a
mean reduction in weight of 0.69 kg com-
pared with the intensive group (P 
0.001).
Primary outcomes
A total of 2,125 participants had a major
macrovascular or microvascular event
during follow-up: 18.1% in the intensive
control group and 20.0% in the standard
control group (hazard ratio 0.90 [95% CI
0.82–0.98]; P  0.013) (Fig. 3). There
were no significant differences in the
number of macrovascular events between
the two groups during the trial (hazard
ratio 0.94 [0.84–1.06]; P  0.32) (Fig.
3). Thus, the differences were due to
fewer microvascular events (14% rela-
tive risk reduction, P  0.01), essen-
tially a reduction in diabetic nephropathy
(Fig. 4).
Secondary outcomes (including
sudden death)
There were 1,031 deaths during the trial,
but there were no significant differences
between the two groups (8.9% in the in-
tensive control group and 9.6% in the
standard control group (hazard ratio 0.93
[0.83–1.06]; P 0.28) (Fig. 3). Hospital-
ization was more frequent in the intensive
control group, but there were no other
significant differences in secondary end
points.
Hypoglycemia
Severe hypoglycemia was more frequent
in the intensive-control group than in the
standard-control group: 150 patients
(2.7%) had at least one episode of severe
hypoglycemia compared with 81 (1.5%)
in the standard group (hazard ratio 1.86
[1.42–2.40]; P  0.001).
Minor hypoglycemia was also more
frequent in the intensive control group
(120 events per 100 patients per year, ver-
sus 90 with standard control).
CONCLUSIONS— The ADVANCE
study has answered a number of impor-
tant questions regarding glycemic control
in patients with type 2 diabetes. It has
clearly demonstrated that it is possible to
achieve tight levels of glycemic control
safely using conventional agents. The glu-
cose-lowering approach reflected con-
ventional “real-life” strategies using
sulfonylureas (gliclazideMR), metformin,
and insulin. Yet, A1C levels fell progres-
sively to a mean of 6.5% and remained
there for the duration of the study. This is
in contrast to the glycemic profile of the
UKPDS, where glucose control deterio-
rated gradually for the length of the trial
(2). It is possible that the differences be-
tween the populations of patients studied
in the two trials might account for some of
these findings. Patients in the UKPDS
were newly diagnosed, and it is conceiv-
able that in recruiting for ADVANCE, lo-
cal investigators excluded those whose
glycemic control was likely to deteriorate.
The ADVANCE study also included a
large group of individuals from Asia
whose diabetes might be expected to be-
have differently from a U.K. population.
However, preliminary analyses do not
suggest that the European patients in AD-
VANCE behaved significantly differently
in terms of glycemic control. It may be
that the incremental approach to glyce-
mic therapy in type 2 diabetes that has
developed over the last 15 years and uses
metformin early together with basal insu-
lin in combination with oral agents is rea-
sonably effective at maintaining tight
levels of glycemic control.
Importantly, the intensive glucose-
lowering strategy used in ADVANCE was
apparently safe. The incremental ap-
proach with increasing number of oral
agents and the use of basal insulin low-
ered A1C levels in the intensive group
gradually and the target A1C of 6.5% was
Figure 2—A1C at baseline and during follow-up, according to glucose-control strategy. Data are
shown for mean glycated hemoglobin. The average difference between the intensive-control group
and the standard-control group for the follow-up period was 0.67 percentage points (95% CI
0.64–0.70).
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achieved over 2 years after the start of the
trial. Perhaps as a result of this relatively
slow fall in A1C, the side effects of glu-
cose-lowering therapy were relatively
limited. Severe hypoglycemia was not
common and less than that reported in
the UKPDS. Indeed, rates of severe hypo-
glycemia in those patients assigned to in-
tensive control in ADVANCE were below
those reported in the standard arm of the
UKPDS. It is not clear which aspects of the
glucose control strategy were responsible
for the low risk of severe hypoglycemia. It
is possible that the use of basal insulin
rather than quick-acting insulin, which is
associated with lower rates of hypoglyce-
mia compared with other insulin regi-
mens (8), partly explains this finding.
The lack of weight gain in the trial was
noteworthy and unexpected. It is possible
that the use of basal insulin as a strategy in
combination with metformin and sulfo-
nylureas was partially responsible (9).
The high proportion of Asian patients and
thus the slightly lower BMI in the trial
compared with other large studies of type
2 diabetes might also have contributed.
However, perhaps the relatively low A1C
in the recruited population on entry into
the trial is the most likely explanation.
Such individuals would be losing rela-
tively small amounts of glucose in their
urine so that tightening their control
would not have caused weight gain due to
a loss of glycosuria, an important cause of
increased weight among patients with
type 2 diabetes when diabetic control is
tightened (10).
This trial and others (11) have dem-
onstrated clearly that at least in the short
term (3–5 years), tightening glycemic
control from moderate to fairly tight lev-
els of A1C (6–6.5%) has no significant
effect in reducing macrovascular disease.
The results of ADVANCEdo not exclude a
minor effect on cardiovascular disease; in-
deed cardiovascular mortality was re-
duced by 12%, albeit nonsignificantly.
Figure 3—Cumulative incidences of events, according to glucose-control strategy. The hazard ratios for intensive glucose control compared with
standard glucose control were as follows: for combined major macrovascular or microvascular events, 0.90 (95% CI 0.82–0.98) (A); for major
macrovascular events, 0.94 (0.84–1.06) (B); for major microvascular events, 0.86 (0.77–0.97) (C); and for death from any cause, 0.93 (0.83–1.06)
(D). The vertical dashed lines indicate the 24- and 48-month study visits, at which additional data on microvascular events were collected, specifically
the ratio of urinary albumin to creatinine and results of a retinal examination. For events relating to these data, the event time was recorded as the
date of the visit. The curves were truncated at month 66, by which time 99% of the events had occurred. The effects of treatment (hazard ratios and
P values) were estimated from unadjusted Cox proportional-hazard models that used all the available data.
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However, clinicians can now concentrate
on targeting other aspects of type 2 diabe-
tes, particularly BP and cholesterol reduc-
tion in the clear knowledge that this will
have a larger effect in preventing macro-
vascular complications.
Nevertheless, it may be that the fall in
the incidence of nephropathy that was
demonstrated in ADVANCE might have
longer-term downstream benefits on car-
diovascular disease. Patients with diabetic
nephropathy have a much higher risk of
macrovascular disease, and so a 20% re-
duction could be expected to affect car-
diovascular disease over a longer time
frame (12). It is noteworthy that the
STENO-2 trial, which tested an aggressive
strategy targeting glucose, BP, and lipids
in high-risk individuals with type 2 dia-
betes, only demonstrated clinically rele-
vant reductions in cardiovascular disease
after 8 years and mortality after 13 years
(13).
Clinicians will need to decide
whether the reduction in diabetic ne-
phropathy among patients with type 2 di-
abetes when A1C levels are lowered to
6.5% is worthwhile. However, since
glycemic control was achieved in AD-
VANCE across multiple centers world-
wide with relatively few side effects, this
level of glycemic control appears to be
both practical and provides useful clinical
benefit. Current clinical guidelines that
recommend A1C levels of between 6.5
and 7% are supported by the data from
ADVANCE.
In conclusion, the ADVANCE trial
has demonstrated in over 10,000 patients
with type 2 diabetes, that an intensive
strategy with conventional agents can
achieve mean A1C levels of 6.5% safely
with no increase in mortality and has no
significant effect in reducing macrovascu-
lar disease, but reduces diabetic nephrop-
athy by 20%.
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